Plasmids, small circular DNA molecules found in bacteria, may contain antibiotic-resistance genes and have the ability to replicate independently. Bacteria can transfer these plasmids to one another, ...

Plasmid DNA (pDNA) is a fundamental starting material for therapeutic development, including for viral vectors, mRNA therapies, and DNA vaccines. Researchers use capture methods such as anion exchange ...

Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.

In the development of DNA vaccines and cell and gene therapies, manufacturing plasmid DNA creates a crucial bottleneck. Such a slowdown could intensify with the market for manufacturing DNA plasmids ...

The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.

Nucleic acid purification procedures have enjoyed a long history, beginning with the first isolation of "nuclein" in 1869 by Freidrich Meischer. In 1958, Matthew Meselson and Frank Stahl demonstrated ...

As cell and gene therapies, mRNA vaccines and other cutting-edge meds come into their own, developers have put a strain on the industry's supply chain. That’s where biopharma building block outfits ...

SEATTLE, March 25, 2020 /PRNewswire/ -- According to Coherent Market Insights, the global viral vector and plasmid DNA manufacturing market is estimated to be valued at US$ 427.2 million in 2019, and ...

Investing.com -- Genenta Science (NASDAQ:GNTA) stock soared 241.8% in premarket trading Friday after announcing a strategic collaboration with ANEMOCYTE focused on off-the-shelf lentiviral vector ...